HOME >> MEDICINE >> NEWS
48-week results for the SOLO trial comparing GW433908/r QD to nelfinavir BID

Glasgow, United Kingdom (Nov. 21, 2002)- Results of the SOLO trial, an open-label, multi-center study evaluating the safety and efficacy of once-a-day (QD) dosing of the investigational protease inhibitor (PI) GW433908 (908) boosted with ritonavir (908/r) QD in antiretroviral therapy-nave patients versus twice-a-day (BID) nelfinavir (NFV, Viracept), were presented today at a late breaker session at the 6th International Congress on Drug Therapy in HIV Infection. SOLO is one of the first pivotal studies to investigate the potential of QD dosing of an HIV protease inhibitor. Both drug arms were administered as part of combination therapy that included abacavir (ABC) and lamivudine (3TC).

In the final analysis of this 48-week trial data, 68 percent of HIV+ patients achieved undetectable viral load with 908/r compared to 65 percent of patients taking NFV BID in this open label study. The 908 compound was co-discovered by GlaxoSmithKline (GSK) and Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX).

At a Glance

  • 68% of HIV+ patients achieved undetectable viral load (VL) with the investigational protease inhibitor 908/r compared to 65% of patients taking nelfinavir (NFV) BID in this open label study.

  • 71% of patients in the 908/r arm with high VL (>500,000 copies/mL) at baseline achieved undetectable VL compared to 53% of patients with high VL at baseline in NFV arm.

  • Virologic failure at 48 weeks was seen in 4% of patients in the 908/r QD arm and 15% of patients in the NFV BID arm.

  • The SOLO study population was treatment-naive, ethnically and gender diverse, with a high proportion of patients with advanced disease.

  • The most significant adverse event was diarrhea, which occurred in 16% in the NFV BID arm and 9% in the 908/r QD arm.

Efficacy Results from SOLO
In the SOLO study, 660 patients (649 treated) were randomized to receive either 1400 mg of 9
'"/>

Contact: Amy Kling
akling@pcipr.com
312-558-1770
Public Communications Inc.
21-Nov-2002


Page: 1 2 3 4 5

Related medicine news :

1. New studies show mixed results on epilepsy drugs and birth defects
2. Study of obese diabetics explains why low-carb diets produce fast results
3. Sharing clinical trial results with participants may be beneficial
4. Emergency clopidogrel could save thousands of lives46,000-patient heart attack trial results
5. Similar results found in both older and younger patients undergoing weight-loss surgery
6. OHSU researcher says FDA could broaden access to results of clinical drug trials
7. Kinder, gentler procedure gives superior results for stem cell transplants
8. Good results with only one egg in in-vitro fertilization
9. Holiday feasting could sabotage liposuction results
10. Early results shed light on lung cancer screening advance
11. Encouraging results from vaccine trial to reduce cervical cancer

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/6/2019)... ... 06, 2019 , ... Allegheny Health Network (AHN) has named Kymberly Gyure, MD, ... WVU Medicine in May 2018, previously served as AHN’s Vice Chair of Pathology and ... October and is also part of the pathology faculty at Drexel University College of ...
(Date:12/6/2019)... ... 2019 , ... Brain Sentinel, Inc. announces it is hosting ... Annual Meeting. The symposium, “Fundamentals of Quantitative Surface Electromyography (sEMG) for Long-Term Monitoring”, ... during ictal events;, 2. Review specific sEMG patterns of motor seizures and the ...
(Date:12/5/2019)... ... December 05, 2019 , ... ... resolution ultrasound (HRUS) technology to help their patients more easily detect ruptured silicone ... participating in this study and reporting on his experience. While the FDA currently ...
(Date:12/5/2019)... ... December 05, 2019 , ... Intelligent.com, a trusted resource for ... Degree Programs for 2020. The comprehensive research guide is based on an assessment ... based on curriculum quality, graduation rate, reputation, and post-graduate employment. , The ...
(Date:12/4/2019)... ... December 04, 2019 , ... A November 12 article on NBC ... public transit options. The article highlighted the life-changing or life-ending consequences of some E-scooter ... to a rider fatality after an incident with a vehicle. Los Angeles-based personal injury ...
Breaking Medicine News(10 mins):
(Date:12/6/2019)... PORTLAND, Ore. (PRWEB) , ... December 06, 2019 ... ... company focused on development of treatments for psychiatric and neurodegenerative disorders, announced today ... Drug (IND) application for NBTX-001 Inhaler, allowing the Company to initiate its Phase ...
(Date:12/6/2019)... ... December 06, 2019 , ... Plant ... Fruit Garden Supply LLC (a division of Horticultural Holdings LLC) to recommend Plant ... growers. , FFGS is a team of disciplined and energetic plant lovers ...
(Date:12/5/2019)... ... 2019 , ... nView, a leading behavioral health solutions company, ... Chief Product Officer. As the company expands its portfolio of software solutions, Rosenbaum ... market into nView’s product and company growth strategy. Rosenbaum will report directly to ...
Breaking Medicine Technology:
Cached News: